ART may lead to more accurate results when well-documented ESs are available. In other situations, Stoffenmanager appears to be a safer alternative because of its greater robustness, particularly when entry data uncertainty is difficult to assess. ECETOC TRA cannot be directly compared to higher tiered models because of its simplistic nature: the use of this tool should be limited only to exceptional cases in which a strong conservative and worst-case evaluation is necessary.
The bioconcentration factor (BCF), a key parameter required by the REACH regulation, estimates the tendency for a xenobiotic to concentrate inside living organisms. In silico methods can be valid alternatives to costly data measurements. However, in the industrial context, these theoretical approaches may fail to predict BCF with reasonable accuracy. We analyzed whether models built on public data only have adequate performances when challenged to predict industrial compounds. A new set of 1129 compounds has been collected by merging publicly available datasets. Generative Topographic Mapping was employed to compare this chemical space with a set of new compounds issued from the industry. Some new chemotypes absent in the training set (such as siloxanes) have been detected. A new BCF model has been built using ISIDA (In SIlico design and Data Analysis) fragment descriptors, support vector regression and random forest machinelearning methods. It has been externally validated on: (i) collected data from the literature and (ii) industrial data. The latter also served as benchmark for the freely available tools VEGA, EPISuite, TEST, OPERA. New model performs (RMSE of 0.58 log BCF units) comparably to existing ones but benefits of an extended applicability, covering the industrial set chemical space (78% data coverage).
The European Registration, Evaluation, Authorization and Restriction of Chemical Substances Regulation, requires marketed chemicals to be evaluated for Ready Biodegradability (RB), considering in silico prediction as valid alternative to experimental testing. However, currently available models may not be relevant to predict compounds of industrial interest, due to accuracy and applicability domain restriction issues. In this work, we present a new and extended RB dataset (2830 compounds), issued by the merging of several public data sources. It was used to train classification models, which were externally validated and benchmarked against already-existing tools on a set of 316 compounds coming from the industrial context. New models showed good performances in terms of predictive power (Balance Accuracy (BA) = 0.74-0.79) and data coverage (83-91%). The Generative Topographic Mapping approach identified several chemotypes and structural motifs unique to the industrial dataset, highlighting for which chemical classes currently available models may have less reliable predictions. Finally, public and industrial data were merged into global dataset containing 3146 compounds. This is the biggest dataset reported in the literature so far, covering some chemotypes absent in the public data. Thus, predictive model developed on the Global dataset has larger applicability domain than the existing ones.
We report predictive models of acute oral systemic toxicity representing a follow-up of our previous work in the framework of the NICEATM project. It includes the update of original models through the addition of new data and an external validation of the models using a dataset relevant for the chemical industry context. A regression model for LD 50 and multi-class classification model for toxicity classes according to the Global Harmonized System categories were prepared. ISIDA descriptors were used to encode molecular structures. Machine learning algorithms included support vector machine (SVM), random forest (RF) and naïve Bayesian. Selected individual models were combined in consensus. The different datasets were compared using the generative topographic mapping approach. It appeared that the NICEATM datasets were lacking some relevant chemotypes for chemical industry. The new models trained on enlarged data sets have applicability domains (AD) sufficiently large to accommodate industrial compounds. The fraction of compounds inside the models' AD increased from 58% (NICEATM model) to 94% (new model). The increase of training sets improved models' prediction performance: RMSE values decreased from 0.56 to 0.47 and balanced accuracies increased from 0.69 to 0.71 for NICEATM and new models, respectively.
The scaffold representation is widely employed to classify bioactive compounds on the basis of common core structures or correlate compound classes with specific biological activities. In this paper, we present a novel approach called “Molecular Anatomy” as a flexible and unbiased molecular scaffold-based metrics to cluster large set of compounds. We introduce a set of nine molecular representations at different abstraction levels, combined with fragmentation rules, to define a multi-dimensional network of hierarchically interconnected molecular frameworks. We demonstrate that the introduction of a flexible scaffold definition and multiple pruning rules is an effective method to identify relevant chemical moieties. This approach allows to cluster together active molecules belonging to different molecular classes, capturing most of the structure activity information, in particular when libraries containing a huge number of singletons are analyzed. We also propose a procedure to derive a network visualization that allows a full graphical representation of compounds dataset, permitting an efficient navigation in the scaffold’s space and significantly contributing to perform high quality SAR analysis. The protocol is freely available as a web interface at https://ma.exscalate.eu.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.